Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

CGEN vs NKTX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CGEN
Compugen Ltd.

Biotechnology

HealthcareNASDAQ • IL
Market Cap$256M
5Y Perf.-80.2%
NKTX
Nkarta, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$223M
5Y Perf.-87.8%

CGEN vs NKTX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CGEN logoCGEN
NKTX logoNKTX
IndustryBiotechnologyBiotechnology
Market Cap$256M$223M
Revenue (TTM)$5M$0.00
Net Income (TTM)$-31M$-103M
Gross Margin-5.2%
Operating Margin-6.5%
Total Debt$3M$80M
Cash & Equiv.$18M$28M

CGEN vs NKTXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CGEN
NKTX
StockJul 20May 26Return
Compugen Ltd. (CGEN)10019.8-80.2%
Nkarta, Inc. (NKTX)10012.2-87.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: CGEN vs NKTX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: NKTX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Compugen Ltd. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
CGEN
Compugen Ltd.
The Income Pick

CGEN is the clearest fit if your priority is income & stability and long-term compounding.

  • beta 1.68
  • -57.2% 10Y total return vs NKTX's -93.4%
  • Lower volatility, beta 1.68, Low D/E 5.3%, current ratio 5.26x
Best for: income & stability and long-term compounding
NKTX
Nkarta, Inc.
The Growth Play

NKTX carries the broadest edge in this set and is the clearest fit for growth exposure.

  • EPS growth 33.3%
  • 8.0% revenue growth vs CGEN's -16.7%
  • 3.9% margin vs CGEN's -5.8%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthNKTX logoNKTX8.0% revenue growth vs CGEN's -16.7%
Quality / MarginsNKTX logoNKTX3.9% margin vs CGEN's -5.8%
Stability / SafetyCGEN logoCGENBeta 1.68 vs NKTX's 2.07, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)CGEN logoCGEN+128.8% vs NKTX's +68.4%
Efficiency (ROA)NKTX logoNKTX-24.0% ROA vs CGEN's -32.0%, ROIC -24.3% vs -24.1%

CGEN vs NKTX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCGENLAGGINGNKTX

Income & Cash Flow (Last 12 Months)

Insufficient data to determine a leader in this category.

CGEN and NKTX operate at a comparable scale, with $5M and $0 in trailing revenue.

MetricCGEN logoCGENCompugen Ltd.NKTX logoNKTXNkarta, Inc.
RevenueTrailing 12 months$5M$0
EBITDAEarnings before interest/tax-$33M-$113M
Net IncomeAfter-tax profit-$31M-$103M
Free Cash FlowCash after capex$0-$94M
Gross MarginGross profit ÷ Revenue-5.2%
Operating MarginEBIT ÷ Revenue-6.5%
Net MarginNet income ÷ Revenue-5.8%
FCF MarginFCF ÷ Revenue+177.6%
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year+25.6%
Insufficient data to determine a leader in this category.

Valuation Metrics

Evenly matched — CGEN and NKTX each lead in 1 of 2 comparable metrics.
MetricCGEN logoCGENCompugen Ltd.NKTX logoNKTXNkarta, Inc.
Market CapShares × price$256M$223M
Enterprise ValueMkt cap + debt − cash$241M$275M
Trailing P/EPrice ÷ TTM EPS-17.88x-1.97x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue9.19x
Price / BookPrice ÷ Book value/share4.66x0.52x
Price / FCFMarket cap ÷ FCF5.17x
Evenly matched — CGEN and NKTX each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

CGEN leads this category, winning 5 of 7 comparable metrics.

NKTX delivers a -30.4% return on equity — every $100 of shareholder capital generates $-30 in annual profit, vs $-72 for CGEN. CGEN carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to NKTX's 0.20x.

MetricCGEN logoCGENCompugen Ltd.NKTX logoNKTXNkarta, Inc.
ROE (TTM)Return on equity-71.5%-30.4%
ROA (TTM)Return on assets-32.0%-24.0%
ROICReturn on invested capital-24.1%-24.3%
ROCEReturn on capital employed-15.7%-30.6%
Piotroski ScoreFundamental quality 0–944
Debt / EquityFinancial leverage0.05x0.20x
Net DebtTotal debt minus cash-$15M$52M
Cash & Equiv.Liquid assets$18M$28M
Total DebtShort + long-term debt$3M$80M
Interest CoverageEBIT ÷ Interest expense-437.97x
CGEN leads this category, winning 5 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

CGEN leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in CGEN five years ago would be worth $3,771 today (with dividends reinvested), compared to $1,139 for NKTX. Over the past 12 months, CGEN leads with a +128.8% total return vs NKTX's +68.4%. The 3-year compound annual growth rate (CAGR) favors CGEN at 62.6% vs NKTX's -11.9% — a key indicator of consistent wealth creation.

MetricCGEN logoCGENCompugen Ltd.NKTX logoNKTXNkarta, Inc.
YTD ReturnYear-to-date+84.5%+68.4%
1-Year ReturnPast 12 months+128.8%+68.4%
3-Year ReturnCumulative with dividends+330.1%-31.5%
5-Year ReturnCumulative with dividends-62.3%-88.6%
10-Year ReturnCumulative with dividends-57.2%-93.4%
CAGR (3Y)Annualised 3-year return+62.6%-11.9%
CGEN leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

CGEN leads this category, winning 2 of 2 comparable metrics.

CGEN is the less volatile stock with a 1.68 beta — it tends to amplify market swings less than NKTX's 2.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricCGEN logoCGENCompugen Ltd.NKTX logoNKTXNkarta, Inc.
Beta (5Y)Sensitivity to S&P 5001.68x2.07x
52-Week HighHighest price in past year$3.23$3.65
52-Week LowLowest price in past year$1.23$1.63
% of 52W HighCurrent price vs 52-week peak+88.4%+86.3%
RSI (14)Momentum oscillator 0–10056.466.9
Avg Volume (50D)Average daily shares traded431K802K
CGEN leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates CGEN as "Buy" and NKTX as "Buy". Consensus price targets imply 585.7% upside for NKTX (target: $22) vs 39.9% for CGEN (target: $4).

MetricCGEN logoCGENCompugen Ltd.NKTX logoNKTXNkarta, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$4.00$21.60
# AnalystsCovering analysts1312
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

CGEN leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 1 category is tied.

Best OverallCompugen Ltd. (CGEN)Leads 3 of 6 categories
Loading custom metrics...

CGEN vs NKTX: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is CGEN or NKTX a better buy right now?

Analysts rate Compugen Ltd.

(CGEN) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — CGEN or NKTX?

Over the past 5 years, Compugen Ltd.

(CGEN) delivered a total return of -62. 3%, compared to -88. 6% for Nkarta, Inc. (NKTX). Over 10 years, the gap is even starker: CGEN returned -57. 2% versus NKTX's -93. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — CGEN or NKTX?

By beta (market sensitivity over 5 years), Compugen Ltd.

(CGEN) is the lower-risk stock at 1. 68β versus Nkarta, Inc. 's 2. 07β — meaning NKTX is approximately 23% more volatile than CGEN relative to the S&P 500. On balance sheet safety, Compugen Ltd. (CGEN) carries a lower debt/equity ratio of 5% versus 20% for Nkarta, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — CGEN or NKTX?

On earnings-per-share growth, the picture is similar: Nkarta, Inc.

grew EPS 33. 3% year-over-year, compared to 23. 8% for Compugen Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — CGEN or NKTX?

Nkarta, Inc.

(NKTX) is the more profitable company, earning 0. 0% net margin versus -51. 1% for Compugen Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTX leads at 0. 0% versus -53. 4% for CGEN. At the gross margin level — before operating expenses — CGEN leads at 71. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — CGEN or NKTX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is CGEN or NKTX better for a retirement portfolio?

For long-horizon retirement investors, Compugen Ltd.

(CGEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Nkarta, Inc. (NKTX) carries a higher beta of 2. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CGEN: -57. 2%, NKTX: -93. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between CGEN and NKTX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

CGEN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

NKTX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.